Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Biohaven Therapeutics Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 examiners and 2 art units, indicating that multiple matters share examination resources within a relatively compact technical structure.
ESSEX, LAURA ANN is the busiest examiner, with 2 pending actions. That assignment is the clearest point for coordinated review, while the remaining matters should be handled with attention to their separate examiner records.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESSEX, LAURA ANN | 2 | 60.0% | +35.8% |
| ANDERSON, REBECCA L | 1 | 73.3% | +23.7% |
| SEUDIEU SEUDIEU, CARINE PATRICIA | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17623238 | CD38-BINDING AGENTS AND USES THEREOF | ESSEX, LAURA ANN | 47d |
| 17268072 | USE OF RILUZOLE ORAL DISINTIGRATING TABLETS FOR TREATING DISEASES | ESSEX, LAURA ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17623238 | CD38-BINDING AGENTS AND USES THEREOF | ESSEX, LAURA ANN | 47d |
| 18868762 | INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | ANDERSON, REBECCA L | — |
| 17268072 | USE OF RILUZOLE ORAL DISINTIGRATING TABLETS FOR TREATING DISEASES | ESSEX, LAURA ANN | — |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 1675 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18868762 | INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | ANDERSON, REBECCA L | 1626 | §112 | Non-Final OA | — | Pending | Nov 24, 2024 |
| 18867416 | METHODS OF TREATING SPINOCEREBELLAR ATAXIAS | SEUDIEU SEUDIEU, CARINE PATRICIA | 1626 | §103DP | Non-Final OA | — | Pending | Nov 19, 2024 |
| 17623238 | CD38-BINDING AGENTS AND USES THEREOF | ESSEX, LAURA ANN | 1675 | §102§103§112 | Final Rejection | 47d | Pending | Dec 27, 2021 |
| 17268072 | USE OF RILUZOLE ORAL DISINTIGRATING TABLETS FOR TREATING DISEASES | ESSEX, LAURA ANN | 1675 | §102§103 | Final Rejection | — | Pending | Feb 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiohaven Therapeutics Ltd. has 4 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Laura Ann Essex has the most, with 2 of Biohaven Therapeutics Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
